OECD GUIDELINE FOR THE TESTING OF CHEMICALS

Stably Transfected Human Estrogen Receptor-α Transcriptional Activation Assay for Detection of Estrogenic Agonist-Activity of Chemicals

INTRODUCTION

1. The OECD initiated a high-priority activity in 1998 to revise existing, and to develop new, Test Guidelines for the screening and testing of potential endocrine disrupting chemicals. The OECD conceptual framework for testing and assessment of potential endocrine disrupting chemicals comprises five levels, each level corresponding to a different level of biological complexity (1). The Transcriptional Activation (TA) assay described in this Test Guideline is a level 2 “in vitro assay, providing mechanistic information”. The validation study of the Stably Transfected Transactivation Assay (STTA) by the Japanese Chemicals Evaluation and Research Institute (CERI) using the hERα-HeLa-9903 cell line to detect estrogenic agonist activity mediated through human estrogen receptor alpha (hERα) demonstrated the relevance and reliability of the assay for its intended purpose (2).

2. In vitro TA assays are based upon the production of a reporter gene product induced by a chemical, following binding of the chemical to a specific receptor and subsequent downstream transcriptional activation. TA assays using activation of reporter genes are screening assays that have long been used to evaluate the specific gene expression regulated by specific nuclear receptors, such as the estrogen receptors (ERs) (3) (4) (5) (6). They have been proposed for the detection of estrogenic transactivation regulated by the ER (7) (8) (9). The nuclear ERs exist as at least two subtypes, termed α and β, encoded by distinct genes and with different tissue distribution, relative ligand binding affinities and biological functions. Nuclear ERα mediates the classic estrogenic response, therefore models currently being developed to measure ER activation mainly relate to ERα. The aim of this TA assay is to evaluate the ability of a chemical to function as an ERα ligand and activate an agonist response, for screening and prioritisation purposes but can also provide mechanistic information that can be used in a weight of evidence approach.

3. Definitions and abbreviations used in this Test Guideline are described in Annex 1.

INITIAL CONSIDERATIONS AND LIMITATIONS

4. Estrogen agonists act as ligands for ERs, and may activate the transcription of estrogen responsive genes. This interaction may have the potential to trigger adverse health effects by disrupting estrogen-regulated systems. This Test Guideline describes an assay that evaluates TA mediated by the hERα. This process is considered to be one of the key mechanisms of possible endocrine disruption related health hazards, although there are also other important endocrine disruption mechanisms. These include (i) actions mediated via other nuclear receptors linked to the endocrine system and interactions with steroidogenic enzymes, (ii) metabolic activation or deactivation of hormones, (iii) distribution of hormones to target tissues, and (iv) clearance of hormones from the body. This Test Guideline exclusively addresses TA of an estrogen-regulated reporter gene by agonist binding to the hERα, and therefore it should not be directly extrapolated to the complex in vivo situation of estrogen regulation of cellular processes. Furthermore, this Test...
Guideline does not address antagonist interaction with the hERα and subsequent effect on transcription.

5. This test method is specifically designed to detect hERα-mediated TA by measuring chemiluminescence as the endpoint. However, non-receptor-mediated luminescence signals have been reported at phytoestrogen concentrations higher than 1 μM due to the over-activation of the luciferase reporter gene (10) (11). While the dose-response curve indicates that true activation of the ER system occurs at lower concentrations, luciferase expression obtained at high concentrations of phytoestrogens or similar compounds suspected of producing phytoestrogen-like over-activation of the luciferase reporter gene needs to be examined carefully in stably transfected ER TA assay systems (Annex 2).

6. It is recognized that this assay using the hERα-HeLa-9903 cell line is only one of several ER transcriptional activation assays currently being developed and validated. It is, therefore the intention that a generic performance based Test Guideline will replace this Test Guideline as soon as such guideline is developed and approved.

**PRINCIPLE OF THE TEST**

7. The TA assay using a reporter gene technique is an *in vitro* tool that provides mechanistic data. The assay is used to signal binding of the estrogen receptor with a ligand. Following ligand binding, the receptor-ligand complex translocates to the nucleus where it binds specific DNA response elements and transactivates a firefly luciferase reporter gene, resulting in increased cellular expression of luciferase enzyme. Luciferin is a substrate that is transformed by the luciferase enzyme to a bioluminescence product that can be quantitatively measured with a luminometer. Luciferase activity can be evaluated quickly and inexpensively with a number of commercially available test kits.

8. The test system provided in this Test Guideline utilises the hERα-HeLa-9903 cell line, which is derived from a human cervical tumor, with two stably inserted constructs: (i) the hERα expression construct (encoding the full-length human receptor), and (ii) a firefly luciferase reporter construct bearing five tandem repeats of a vitellogenin Estrogen-Responsive Element (ERE) driven by a mouse metallothionein (MT) promoter TATA element. The mouse MT TATA gene construct has been shown to have the best performance, and so is commonly used. Consequently this hERα-HeLa-9903 cell line can measure the ability of a test chemical to induce hERα-mediated transactivation of luciferase gene expression.

9. Data interpretation for this assay is based upon whether or not the maximum response level induced by a test chemical equals or exceeds an agonist response equal to 10% of that induced by a maximally inducing (1 nM) concentration of the positive control (PC) 17β estradiol (E2) (*i.e.* the PC10). Data analysis and interpretation are discussed in greater detail in paragraphs 34-45.

**PROCEDURE**

**Cell Lines**

10. The stably transfected hERα-HeLa-9903 cell line should be used for the assay. The cell line can be obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank¹, upon signing a Material Transfer Agreement (MTA).

---

¹ JCRB Cell Bank: National Institute of Biomedical Innovation, 7-6-8 Asagi Saito, Ibaraki-shi, Osaka 567-0085, Japan Fax: +81-72-641-9812
11. Only cells characterised as mycoplasma-free should be used in testing. RT PCR (Real Time Polymerase Chain Reaction) is the method of choice for a sensitive detection of mycoplasma infection (12) (13) (14).

**Stability of the cell line**

12. To monitor the stability of the cell line, E2, 17α-estradiol, 17α-methyltestosterone, and corticosterone should be used as the reference chemicals and a complete concentration-response curve in the test concentration range provided in Table 1 should be measured at least once each time the assay is performed, and the results should be in agreement with the results provided in Table 1.

**Cell Culture and Plating Conditions**

13. Cells should be maintained in Eagle’s Minimum Essential Medium (EMEM) without phenol red, supplemented with 60 mg/L of antibiotic Kanamycine and 10% dextran-coated-charcoal-treated fetal bovine serum (DCC-FBS), in a CO$_2$ incubator (5% CO$_2$) at 37±1°C. Upon reaching 75-90% confluency, cells can be subcultured at 10 mL of 0.4 x 10$^5$ – 1 x 10$^5$ cells/mL for 100 mm cell culture dish. Cells should be suspended with 10% FBS-EMEM (which is the same as EMEM with DCC-FBS) and then plated into wells of a microplate at a density of 1 x 10$^4$ cells/100 μL/well. Next, the cells should be pre-incubated in a 5% CO$_2$ incubator at 37°C for 3 hours before the chemical exposure. The plastic-ware should be free of estrogenic activity.

14. To maintain the integrity of the response, the cells should be grown for more than one passage from the frozen stock in the conditioned media and should not be cultured for more than 40 passages. For the hERα-HeLa-9903 cell line, this will be less than three months.

15. The DCC-FBS can be prepared as described in Annex 3, or obtained from commercial sources.

**Acceptability Criteria**

**Positive and Negative Reference Chemicals**

16. Prior to and during the study, the responsiveness of the test system should be verified using the appropriate concentrations of a strong estrogen: E2, a weak estrogen (17α-estradiol), a very weak agonist (17α-methyltestosterone) and a negative compound (corticosterone). Acceptable range values derived from the validation study are given in Table 1 (2). These 4 concurrent reference chemicals should be included with each experiment and the results should fall within the given acceptable limits. If this is not the case, the cause for the failure to meet the acceptability criteria should be determined (e.g. cell handling, and serum and antibiotics for quality and concentration) and the assay repeated. Once the acceptability criteria have been achieved, to ensure minimum variability of EC50, PC50 and PC10 values, consistent use of materials for cell culturing is essential. The four concurrent reference chemicals, which should be included in each experiment (conducted under the same conditions including the materials, passage level of cells and technicians), can ensure the sensitivity of the assay because the PC10s of the three positive reference chemicals should fall within the acceptable range, as should the PC50s and EC50s where they can be calculated (see Table 1).
Table 1. Acceptable range values of the 4 reference chemicals for the STTA assay (means ± 2 standard deviations).

<table>
<thead>
<tr>
<th>Name</th>
<th>logPC50</th>
<th>logPC10</th>
<th>logEC50</th>
<th>Hill slope</th>
<th>Test range</th>
</tr>
</thead>
<tbody>
<tr>
<td>17β-Estradiol (E2) CAS No: 50-28-2</td>
<td>-11.4 ~ -10.1</td>
<td>&lt; -11</td>
<td>-11.3 ~ -10.1</td>
<td>0.7 ~ 1.5</td>
<td>$10^{-14} ~ 10^{-8}$ M</td>
</tr>
<tr>
<td>17α-Estradiol CAS No: 57-91-0</td>
<td>-9.6 ~ -8.1</td>
<td>-10.7 ~ -9.3</td>
<td>-9.6 ~ -8.4</td>
<td>0.9 ~ 2.0</td>
<td>$10^{-14} ~ 10^{-8}$ M</td>
</tr>
<tr>
<td>Corticosterone CAS No: 50-22-6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>$10^{-10} ~ 10^{-4}$ M</td>
</tr>
<tr>
<td>17α-Methyltestosterone CAS No: 58-18-4</td>
<td>-6.0 ~ -5.1</td>
<td>-8.0 ~ -6.2</td>
<td>–</td>
<td>–</td>
<td>$10^{-11} ~ 10^{-9}$ M</td>
</tr>
</tbody>
</table>

Positive and Vehicle Controls

17. The positive control (PC) (1 nM of E2) should be tested at least in triplicate in each plate. The vehicle that is used to dissolve a test chemical should be tested as a vehicle control (VC) at least in triplicate in each plate. In addition to this VC, if the PC uses a different vehicle than the test chemical, another VC should be tested at least in triplicate on the same plate with the PC.

Fold-induction

18. The mean luciferase activity of the PC (1 nM E2) should be at least 4-fold that of the mean VC on each plate. This criterion is established based on the reliability of the endpoint values from the validation study (historically between four- and 30-fold).

19. With respect to the quality control of the assay, the fold-induction corresponding to the PC10 value of the concurrent PC (1 nM E2) should be greater than 1+2SD of the fold-induction value (=1) of the concurrent VC. For prioritisation purposes, the PC10 value can be useful to simplify the data analysis required compared to a statistical analysis. Although a statistical analysis provides information on significance, such an analysis is not a quantitative parameter with respect to concentration-based potential, and so is less useful for prioritisation purposes.

Chemicals to Demonstrate Laboratory Proficiency

20. Prior to testing unknown chemicals in the STTA assay, the responsiveness of the test system should be confirmed by each laboratory, at least once for each newly prepared batch of cell stocks taken from the frozen stock by independent testing of the 10 proficiency chemicals listed in Table 2. This should be done at least in duplicate, on different days, and the results should be comparable to Table 2 and any deviations should be justified.
Table 2. List of Proficiency Chemicals

<table>
<thead>
<tr>
<th>Compound</th>
<th>CAS No.</th>
<th>Class²</th>
<th>Test concentration range</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diethylstilbestrol (DES)</td>
<td>56-53-1</td>
<td>Positive</td>
<td>$10^{-14} - 10^{-9}$ M</td>
<td></td>
</tr>
<tr>
<td>17α-Ethynyl estradiol (EE)</td>
<td>57-63-6</td>
<td>Positive</td>
<td>$10^{-14} - 10^{-9}$ M</td>
<td></td>
</tr>
<tr>
<td>Hexestrol</td>
<td>84-16-2</td>
<td>Positive</td>
<td>$10^{-13} - 10^{-7}$ M</td>
<td></td>
</tr>
<tr>
<td>Genistein</td>
<td>446-72-0</td>
<td>Positive</td>
<td>$10^{-12} - 10^{-9}$ M</td>
<td>Cytotoxic at (0.01)$^3$, 0.1 and 1 mM</td>
</tr>
<tr>
<td>Estrone</td>
<td>53-16-7</td>
<td>Positive</td>
<td>$10^{-12} - 10^{-6}$ M</td>
<td></td>
</tr>
<tr>
<td>Butyl paraben</td>
<td>94-26-8</td>
<td>Positive</td>
<td>$10^{-11} - 10^{-4}$ M</td>
<td>Cytotoxic at (0.1)$^4$ and 1 mM</td>
</tr>
<tr>
<td>1,3,5-Tris(4hydroxyphenyl)benzene</td>
<td>15797-52-1</td>
<td>Positive</td>
<td>$10^{-12} - 10^{-9}$ M</td>
<td>Cytotoxic at 100 µM. PCmax approximately 15% of PC Binds to hERα and has ER antagonist activity</td>
</tr>
<tr>
<td>Dibutyl phthalate (DBP)</td>
<td>84-74-2</td>
<td>Negative</td>
<td>$10^{-11} - 10^{-4}$ M</td>
<td>Cytotoxic at 1 mM</td>
</tr>
<tr>
<td>Atrazine</td>
<td>1912-24-9</td>
<td>Negative</td>
<td>$10^{-11} - 10^{-4}$ M</td>
<td>Cytotoxic $^4$ at 1 mM</td>
</tr>
<tr>
<td>Corticosterone</td>
<td>50-22-6</td>
<td>Negative</td>
<td>$10^{-11} - 10^{-5}$ M</td>
<td>If not cytotoxic at 1 mM, then that should be the highest tested concentration</td>
</tr>
</tbody>
</table>

¹ Compound selected to challenge solubility and cytotoxicity.  
² See Table 5 for definitions of positive and negative.  
³ Negative for ERα mediated TA but may not be negative for non-ERα mediated TA. Thus a positive result in this assay with DBP would indicate that the system is detecting other than pure ERα mediated activity and is therefore unacceptable.  
⁴ Cytotoxicity is close to 80%.

**Vehicle**

21. Dimethyl sulfoxide (DMSO), or appropriate solvent, at the same concentration used for the different positive and negative controls and the test chemicals should be used as the concurrent VC. Test substances should be dissolved in a solvent that solubilizes that test substance and is miscible with the cell medium. Water, ethanol (95% to 100% purity) and DMSO are suitable vehicles. If DMSO is used, the level should not exceed 0.1% (v/v). For any vehicle, it should be demonstrated that the maximum volume used is not cytotoxic and does not interfere with assay performance.

**Preparation of Test Chemicals**

22. Generally, the test chemicals should be dissolved in DMSO or other suitable solvent, and serially diluted with the same solvent at a common ratio of 1:10 in order to prepare solutions for dilution with media.
Solubility and Cytotoxicity: Considerations for Range Finding.

23. A preliminary test should be carried out to determine the appropriate concentration range of chemical to be tested, and to ascertain whether the test chemical may have any solubility and cytotoxicity problems. Initially, chemicals are tested up to the maximum concentration of 1 μl/ml, 1 mg/ml, or 1 mM, whichever is the lowest. Based on the extent of cytotoxicity or lack of solubility observed in the preliminary test, the first definite run should test the chemical at log-serial dilutions starting at the maximum acceptable concentration (e.g. 1 mM, 100 μM, 10 μM, etc.) and the presence of cloudiness or precipitate or cytotoxicity noted. Concentrations in the second, and if necessary third run should be adjusted as appropriate to better characterise the concentration-response curve and to avoid concentrations which are found to be insoluble or to induce excessive cytotoxicity.

24. For ER agonists, the presence of increasing levels of cytotoxicity can significantly alter or eliminate the typical sigmoidal response and should be considered when interpreting the data. Cytotoxicity testing methods that can provide information regarding 80% cell viability should be used, utilising an appropriate assay based upon laboratory experience.

25. Should the results of the cytotoxicity test show that the concentration of the test substance has reduced the cell number by 20% or more, this concentration is regarded as cytotoxic, and the concentrations at or above the cytotoxic concentration should be excluded from the evaluation.

Chemical Exposure and Assay Plate Organisation

26. The procedure for chemical dilutions (Steps-1 and 2) and exposure to cells (Step-3) can be conducted as follows:

Step-1: Each test chemical should be serially diluted in DMSO, or appropriate solvent, and added to the wells of a microtitre plate to achieve final serial concentrations as determined by the preliminary range finding test (typically in a series of, for example 1 mM, 100 μM, 10 μM, 1μM, 100 nM, 10 nM, 1 nM, 100 pM, and 10 pM (10^{-3}-10^{-11} M)) for triplicate testing.

Step-2: Chemical dilution: First dilute 1.5 μL of the test chemical in the solvent to a concentration of 500 μL of media.

Step-3: Chemical exposure of the cells: Add 50 μL of dilution with media (prepared in Step-2) to an assay well containing 10^4 cells/100 μL/well.

The recommended final volume of media required for each well is 150 μL.

Test samples and reference chemicals can be assigned as shown in Table 3.

Table 3: Example of plate concentration assignment of the reference chemicals in the assay plate

<table>
<thead>
<tr>
<th>Row</th>
<th>17α-Methyltestosterone</th>
<th>Corticosterone</th>
<th>17α-Estradiol</th>
<th>E2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>A</td>
<td>conc 1 (10 μM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→</td>
</tr>
<tr>
<td>B</td>
<td>conc 2 (1 μM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>C</td>
<td>conc 3 (100 nM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>D</td>
<td>conc 4 (10 nM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>E</td>
<td>conc 5 (1 nM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>F</td>
<td>conc 6 (100 pM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>G</td>
<td>conc 7 (10 pM)</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
<tr>
<td>H</td>
<td>VC</td>
<td>→ =</td>
<td>→ =</td>
<td>→ =</td>
</tr>
</tbody>
</table>

© OCDE, (2009)
Plate controls = VC: Vehicle control (DMSO); PC: Positive control (1 nM E2)

27. The reference chemicals (E2, 17α-Estradiol, 17α-methyl testosterone and corticosterone) should be tested in every run (Table 3). PC wells treated with 1 nM of E2 that can produce maximum induction of E2 and VC wells treated with DMSO (or appropriate solvent) alone should be included in each test assay plate (Table 4). If cells from different sources (e.g. different passage number, different lot, etc.,) are used in the same experiment, the reference chemicals should be tested for each cell source.

Table 4: Example of plate concentration assignment of test and plate control chemicals in the assay plate

<table>
<thead>
<tr>
<th>Row</th>
<th>Test Chemical 1</th>
<th>Test Chemical 2</th>
<th>Test Chemical 3</th>
<th>Test Chemical 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>conc 1 (10 µM)</td>
<td>→</td>
<td>1 nM</td>
<td>→</td>
</tr>
<tr>
<td>B</td>
<td>conc 2 (1 µM)</td>
<td>→</td>
<td>100 µM</td>
<td>→</td>
</tr>
<tr>
<td>C</td>
<td>conc 3 (100 nM)</td>
<td>→</td>
<td>10 µM</td>
<td>→</td>
</tr>
<tr>
<td>D</td>
<td>conc 4 (10 nM)</td>
<td>→</td>
<td>1 µM</td>
<td>→</td>
</tr>
<tr>
<td>E</td>
<td>conc 5 (1 nM)</td>
<td>→</td>
<td>100 nM</td>
<td>→</td>
</tr>
<tr>
<td>F</td>
<td>conc 6 (100 pM)</td>
<td>→</td>
<td>10 nM</td>
<td>→</td>
</tr>
<tr>
<td>G</td>
<td>conc 7 (10 pM)</td>
<td>→</td>
<td>1 nM</td>
<td>→</td>
</tr>
<tr>
<td>H</td>
<td>VC</td>
<td>→</td>
<td>PC</td>
<td>→</td>
</tr>
</tbody>
</table>

28. The lack of edge effects should be confirmed, as appropriate, and if edge effects are suspected, the plate layout should be altered to avoid such effects. For example, a plate layout excluding the edge wells can be employed.

29. After adding the chemicals, the assay plates should be incubated in a 5% CO₂ incubator at 37±1°C for 20-24 hours to induce the reporter gene products.

30. Special considerations will need to be applied to those compounds that are highly volatile. In such cases, nearby control wells may generate false positives, and this should be considered in light of expected and historical control values. In the few cases where volatility may be of concern, the use of “plate sealers” may help to effectively isolate individual wells during testing, and is therefore recommended in such cases.

31. Repeat definitive tests for the same chemical should be conducted on different days, to ensure independence.

Luciferase assay

32. A commercial luciferase assay reagent [e.g. Steady-Glo® Luciferase Assay System (Promega, E2510, or equivalents)] or a standard luciferase assay system (Promega, E1500, or equivalents) can be used for the assay, as long as the acceptability criteria is met. The assay reagents should be selected based on the sensitivity of the luminometer to be used. When using the standard luciferase assay system, Cell Culture Lysis Reagent (Promega, E1531, or equivalents) should be used before adding the substrate. The luciferase reagent should be applied following the manufacturers’ instructions.
ANALYSIS OF DATA

33. To obtain the relative transcriptional activity to PC (1 nM of E2), the luminescence signals from the same plate can be analysed according to the following steps (other equivalent mathematical processes are also acceptable):

Step 1. Calculate mean value for the VC.

Step 2. Subtract the mean value of the VC from each well value to normalise the data.

Step 3. Calculate the mean for the normalised PC.

Step 4. Divide the normalised value of each well in the plate by the mean value of the normalised PC (PC=100%).

The final value of each well is the relative transcriptional activity for that well compared to the PC response.

Step 5. Calculate the mean value of the relative transcriptional activity for each concentration group of the test chemical. There are two dimensions to the response: the averaged transcriptional activity (response) and the concentration at which the response occurs (see following section).

EC50, PC50 and PC10 induction considerations

34. The full concentration-response curve is required for the calculation of the EC50, but this may not always be achievable or practical due to limitations of the test concentration range (for example due to cytotoxicity or solubility problems). However, as the EC50 and maximum induction level (corresponding to the top value of the Hill-equation) are informative parameters, these parameters should be reported where possible. For the calculation of EC50 and maximum induction level, appropriate statistical software should be used (e.g. Graphpad Prism statistical software).

35. If the Hill’s logistic equation is applicable to the concentration response data, the EC50 should be calculated by the following equation (15):

\[ Y = \text{Bottom} + \left( \frac{\text{Top} - \text{Bottom}}{1 + 10^{\left(\log \text{EC50} - \text{X}\right) \times \text{Hill slope}}} \right) \]

Where:
- \( X \) is the logarithm of concentration; and,
- \( Y \) is the response and \( Y \) starts at the Bottom and goes to the Top in a sigmoid curve.
- Bottom is fixed at zero in the Hill’s logistic equation.

36. For each test chemical, the following should be provided:

(i) The RPCMax which is the maximum level of response induced by a test chemical, expressed as a percentage of the response induced by 1 nM E2 on the same plate, as well as the PCMax (concentration associated with the RPCMax); and

(ii) For positive chemicals, the concentrations that induce the PC10 and, if appropriate, the PC50.

37. The PCx value can be calculated by interpolating between 2 points on the X-Y coordinate, one immediately above and one immediately below a PCx value. Where the data points lying immediately above and below the PCx value have the coordinates \((a,b)\) and \((c,d)\) respectively, then the PCx value may be calculated using the following equation:

\[ \log[\text{PCx}] = \log[c] + (x-d)/(d-b) \]
38. Descriptions of PC values are provided in Figure 1 below.

**Figure 1:** Example of how to derive PC-values. The PC (1 nM of E2) is included on each assay plate.

![Graph showing fold induction of PC (1 nM E2) vs. fold induction of VC with mean (±1) + 2SD of fold induction of VC and fold induction corresponding to PC10 mean (±1) of fold induction of VC.]

39. The results should be based on two (or three) independent runs. If two runs give comparable and therefore reproducible results, it is not necessary to conduct a third run. To be acceptable, the results should:

- Meet the performance standard requirements:
  - The mean luciferase activity of the PC (1 nM E2) should be at least 4-fold that of the mean VC on each plate.
  - The fold induction corresponding to the PC10 value of the concurrent PC (1 nM E2) should be greater than 1+2SD of the fold induction value (=1) of the VC.
- Be reproducible.

**Data Interpretation Criteria**

**Table 5.** Positive and negative decision criteria

<table>
<thead>
<tr>
<th>Positive</th>
<th>If the RPCMax is obtained that is equal to or exceeds 10% of the response of the positive control in at least two of two or two of three runs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>If the RPCMax fails to achieve at least 10% of the response of the positive control in two of two or two of three runs.</td>
</tr>
</tbody>
</table>

40. Data interpretation criteria are shown in Table 5. Positive results will be characterised by both the magnitude of the effect and the concentration at which the effect occurs. Expressing results as a concentration at which a 50% (PC50) or 10% (PC10) of PC values are reached accomplishes both of these goals. However, a test chemical is determined to be positive, if the maximum response induced by the test chemical (RPCMax) is equal to or exceeds 10% of the response of the PC in at least two of two or two of three runs, while a test chemical is considered negative if the RPCMax fails to achieve at least 10% of the response of the positive control in two of two or two of three runs.
41. The calculations of PC10, PC50 and PCMax can be made by using a spreadsheet available with the Test Guideline on the OECD public website\(^2\).

42. It should be sufficient to obtain PC10 or PC50 values at least twice. However, should the resulting base-line for data in the same concentration range show variability with an unacceptably high coefficient of variation (CV; %) the data may not be considered reliable and the source of the high variability should be identified. The CV of the raw data triplicates (i.e. luminescence intensity data) of the data points that are used for the calculation of PC10 should be less than 20%.

43. Meeting the acceptability criteria indicates the assay system is operating properly, but it does not ensure that any particular run will produce accurate data. Duplicating the results of the first run is the best insurance that accurate data were produced, see paragraphs 41 and 42.

44. Where more information is required in addition to the screening and prioritisation purposes of this TG for positive test compounds, particularly for PC10-PC49 chemicals, as well as chemicals suspected to over-stimulate luciferase, it can be confirmed that the observed luciferase-activity is solely an ER\(\alpha\)-specific response, using an ER\(\alpha\) antagonist (see Annex 3).

**TEST REPORT**

45. The test report should include the following information:

*Test substance:*

- identification data and CAS Number, if known;
- physical nature and purity;
- physicochemical properties relevant to the conduct of the study;
- stability of the test substance.

*Solvent/Vehicle:*

- characterisation (nature, supplier and lot);
- justification for choice of solvent/vehicle;
- solubility and stability of the test substance in solvent/vehicle, if known.

*Cells:*

- type and source of cells;
- number of cell passages;
- methods for maintenance of cell cultures.

*Test conditions:*

cytotoxicity data (and justifications for the method of choice) and solubility limitations should be reported, as well as:

\(^2\) [http://www.oecd.org/env/testguidelines]
• composition of media, CO₂ concentration;
• concentration of test chemical;
• volume of vehicle and test substance added;
• incubation temperature and humidity;
• duration of treatment;
• cell density during treatment;
• positive and negative reference chemicals;
• duration of treatment period;
• Luciferase assay reagents (Product name, supplier and lot);
• acceptability and data interpretation criteria.

Reliability check:

• Fold inductions for each assay plate.
• Actual logEC50, logPC50, logPC10 and Hill slope values for concurrent reference chemicals.

Results:

• Raw and normalised data of luminescent signals;
• Concentration-response relationship, where possible;
• RPCMax, PCMax, PC50 and/or PC10 values, as appropriate;
• EC50 values, if appropriate;
• Statistical analyses, if any, together with a measure of error (e.g. SD, CV or 95% confidence interval) and a description of how these values were obtained.

Discussion of the results

Conclusion
LITERATURE


2. CERI (2006), Draft validation report of TA assay using HeLa-hER-9903 to detect estrogenic activity. [Available at: http://www.oecd.org/document/62/0,3343,en_2649_34377_2348606_1_1_1_1,00.html]


ANNEX 1

Definitions and abbreviations

**Agonist:** A substance that binds to a specific receptor and triggers a response in the cell. It mimics the action of an endogenous ligand binds to the same receptor.

**Antagonist:** A type of receptor ligand or chemical that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses.

**Anti-estrogenic activity,** the capability of a chemical to suppress the action of 17β-estradiol mediated through estrogen receptors.

**CV:** Coefficient of variation

**Cytotoxicity:** the harmful effects to cell structure or function ultimately causing cell death and can be a result of a reduction in the number of cells present in the well at the end of the exposure period or a reduction of the capacity for a measure of cellular function when compared to the concurrent vehicle control.

**DCC-FBS:** Dextran-coated charcoal treated fetal bovine serum.

**DMSO:** Dimethyl sulfoxide

**E2:** 17β-estradiol

**EC50 value,** the concentration of agonist that provokes a response halfway between the baseline (Bottom) and maximum response (Top).

**EE:** 17α-ethynyl estradiol

**ER:** Estrogen receptor

**ERE:** Estrogen Response Element

**Estrogenic activity,** the capability of a chemical to mimic 17β-estradiol in its ability to bind to and activate estrogen receptors. hERα mediated specific estrogenic activity can be detected in this Test Guideline.

**FBS:** Fetal bovine serum

**hERα:** Human estrogen receptor alpha

**MT:** Metallothionein

**OHT:** 4-Hydroxytamoxifen

**PC:** Positive control (1 nM of E2)

**PC10:** the concentration of a test chemical at which the response in an agonist assay is 10% of the response induced by positive control (E2 at 1nM) in each plate

**PC50:** the concentration of a test chemical at which the response in an agonist assay is 50% of the response induced by positive control (E2 at 1nM) in each plate

**PCMax:** the concentration of a test chemical inducing the RPCMax
**RPCMax**: maximum level of response induced by a test chemical, expressed as a percentage of the response induced by 1 nM E2 on the same plate

**RT PCR**: Real Time polymerase chain reaction

**SD**: Standard deviation

**STTA**: Stably Transfected Transcriptional Activation Assay.

**TA**: Transcriptional activation

**Validation**, a process based on scientifically sound principles by which the reliability and relevance of a particular test, approach, method, or process are established for a specific purpose. Reliability is defined as the extent of reproducibility of results from a test within and among laboratories over time, when performed using the same standardised protocol. The relevance of a test method describes the relationship between the test and the effect in the target species and whether the test method is meaningful and useful for a defined purpose, with the limitations identified. In brief, it is the extent to which the test method correctly measures or predicts the (biological) effect of interest, as appropriate (16).

**VC (Vehicle control)**: The vehicle that is used to dissolve test and control chemicals is tested solely as vehicle without dissolved chemical.
ANNEX 2

False positives: Assessment of non-receptor mediated luminescence signals

1. False positives might be generated by non-ER-mediated activation of the luciferase gene, or direct activation of the gene product or unrelated fluorescence. Such effects are indicated by an incomplete or unusual dose-response curve. If such effects are suspected, the effect of an ER antagonist (e.g. 4-hydroxytamoxifen (OHT) at non-toxic concentration) on the response should be examined. The pure antagonist ICI 128780 may not be suitable for this purpose as a sufficient concentration of ICI 128780 may decrease the VC value, and this will affect the data analysis.

2. To ensure validity of this approach, the following needs to be tested in the same plate:
   - Agonistic activity of the unknown chemical with / without 10 µM of OHT
   - VC (in triplicate)
   - OHT (in triplicate)
   - 1 nM of E2 (in triplicate) as agonist PC
   - 1 nM of E2 + OHT (in triplicate)

3. **Data interpretation criteria**

   Note: All wells should be treated with the same concentration of the vehicle.
   - If the agonistic activity of the unknown chemical is NOT affected by the treatment with ER antagonist, it is classified as “Negative”.
   - If the agonistic activity of the unknown chemical is completely inhibited, apply the decision criteria.
   - If the agonistic activity at the lowest concentration is equal to, or is exceeding, PC10 response the unknown chemical is inhibited equal to or exceeding PC10 response. The difference in the responses between the non-treated and treated wells with the ER antagonist is calculated and this difference should be considered as the true response and should be used for the calculation of the appropriate parameters to enable a classification decision to be made.

4. **Data analysis**

   Check the performance standard.
   Check the CV between wells treated under the same conditions.
   1. Calculate the mean of the VC
   2. Subtract the mean of VC from each well value not treated with OHT
   3. Calculate the mean of OHT
   4. Subtract the mean of the VC from each well value treated with OHT
   5. Calculate the mean of the PC
   6. Calculate the relative transcriptional activity of all other wells relative to the PC.
ANNEX 3

Preparation of Serum treated with Dextran Coated Charcoal (DCC)

1. The treatment of serum with dextran-coated charcoal (DCC) is a general method for removal of estrogenic compounds from serum that is added to cell medium, in order to exclude the biased response associated with residual estrogens in serum. 500 mL of fetal bovine serum (FBS) can be treated by this procedure.

Components

2. The following materials and equipment will be required:

   **Materials**
   - Activated charcoal
   - Dextran
   - Magnesium chloride hexahydrate (MgCl₂·6H₂O)
   - Sucrose
   - 1 M HEPES buffer solution (pH 7.4)
   - Ultrapure water produced from a filter system

   **Equipment**
   - Autoclaved glass container (size should be adjusted as appropriate)
   - General Laboratory Centrifuge (that can set temperature at 4°C)

Procedure

3. The following procedure is adjusted for the use of 50 mL centrifuge tubes:

   **[Day-1]** Prepare dextran-coated charcoal suspension with 1 L of ultrapure water containing 1.5 mM of MgCl₂, 0.25 M sucrose, 2.5 g of charcoal, 0.25 g dextran and 5 mM of HEPES and stir it at 4°C, overnight.

   **[Day-2]** Dispense the suspension in 50 mL centrifuge tubes and centrifuge at 10000 rpm at 4°C for 10 minutes. Remove the supernatant and store half of the charcoal sediment at 4°C for the use on Day-3. Suspend the other half of the charcoal with FBS that has been gently thawed to avoid precipitation, and heat-inactivated at 56°C for 30 minutes, then transfer into an autoclaved glass container such as an Erlenmeyer flask. Stir this suspension gently at 4°C, overnight.

   **[Day-3]** Dispense the suspension with FBS into centrifuge tubes for centrifugation at 10000 rpm at 4°C for 10 minutes. Collect FBS and transfer into the new charcoal sediment prepared and stored on Day-2. Suspend the charcoal sediment and stir this suspension gently in an autoclaved glass container at 4°C, overnight.

   **[Day-4]** Dispense the suspension for centrifugation at 10000 rpm at 4°C for 10 minutes and sterilise the supernatant by filtration through 0.2 μm sterile filter. This DCC treated FBS should be stored at -20°C and can be used for up a year.